At least 13 companies are developing new approaches to improve the next generation of antibody-drug conjugates, either through site-specific conjugation, mAb trailers that carry therapeutic payloads, or improvements to ADC payloads. Sources: BioCentury reporting; company documents/websites

Company

Technology

Status

Site-specific conjugation

Allozyne Inc.

Site-specific ADC technology that uses azide non-natural amino acids as conjugation point

Preclin

Ambrx Inc.

ADCs produced in cell-based system that inserts non-native amino acid for site-specific conjugation

Preclin